As of Jan 17, 2025, AbbVie Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $357.7. This suggests it may be undervalued by 108.5% compared to its current price of around $171.5, using a WACC of 6.5% and growth rates of 3.0%.
As of Jan 17, 2025, AbbVie Inc.'s Weighted Average Cost of Capital (WACC) is approximately 6.5%.
As of Jan 17, 2025, AbbVie Inc.'s Enterprise Value (EV) is approximately $680.2B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.